公开(公告)号：US20240301364A1

公开(公告)日：2024-09-12

申请号：US18665920

申请日：2024-05-16

Applicant: UNIVERSITY OF WASHINGTON

Inventor： Edward CLARK ,  Jay Wesley CHAPLIN

IPC: C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K39/385 ,  A61K47/68 ,  C07K16/28

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K39/29 ,  A61K39/385 ,  A61K47/6811 ,  A61K47/6849 ,  C07K16/2896 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/6056 ,  C07K2319/40 ,  C07K2319/74 ,  C12N2770/24132 ,  C12N2770/24134 ,  C12N2770/28033 ,  Y02A50/30

Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

公开(公告)号：US20240189421A1

公开(公告)日：2024-06-13

申请号：US18064299

申请日：2022-12-12

Applicant: Jaw-Ming Cherng

Inventor： Jaw-Ming Cherng ,  Jonathan Cherng

IPC: A61K39/29 ,  A61P31/14 ,  C12N7/00

CPC classification number: A61K39/29 ,  A61P31/14 ,  C12N7/00 ,  A61K2039/545 ,  C12N2770/24234 ,  C12N2770/24251 ,  C12N2770/24271

Abstract: A method for preparing an immunogenic composition, which comprises treating HCV pseudoparticles with α2-3,6,8,9 neuraminidase A to generate the immunogenic composition. In addition, the immunogenic compositions are made in vaccines for eliciting an immune response to HCV in a subject.

公开(公告)号：US20230340085A1

公开(公告)日：2023-10-26

申请号：US18174182

申请日：2023-02-24

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITÉ CLAUDE BERNARD LYON 1 ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ECOLE NORMALE SUPERIEURE DE LYON

Inventor： Floriane FUSIL ,  Els VERHOEYEN ,  Thierry DEFRANCE ,  François-Loïc COSSET

IPC: A61P35/00 ,  C12N15/62 ,  C12N15/86 ,  C07K16/00 ,  C07K16/10 ,  A61K39/29 ,  A61P37/02 ,  C12N15/85 ,  A61P31/00 ,  C12N15/113

CPC classification number: C07K16/109 ,  A61K39/29 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  C07K16/00 ,  C12N15/113 ,  C12N15/62 ,  C12N15/85 ,  C12N15/86 ,  A61K2039/505

Abstract: The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence compris -ing successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig′ in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig′, said intronic sequence comprising an internal 5′ splice site enabling the spli -cing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3′ terminal exon of said gene; B4) a se -quence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobulin Ig′ BCR, wherein said sequence B4) comprises, between the coding sequences of the M1 and M2 domains, an intronic sequence containing a splice site enabling the splicing of said intronic sequence between the M1 and M2 domains coding sequences; and B5) a membrane-anchored specific poly(A) signal (p AM), after the stop codon of the M2 domain, wherein the multicistronic nucleic acid enables the co-expression of the sequences A and B into separate proteins.

公开(公告)号：US11767357B2

公开(公告)日：2023-09-26

申请号：US16241410

申请日：2019-01-07

Applicant: B & H Biotechnologies, LLC

Inventor： Huiru Wang

IPC: C07K16/00 ,  A61K39/42 ,  A61K39/12 ,  C07K16/10 ,  A61K35/16 ,  A61K39/145 ,  A61K39/15 ,  A61K39/235 ,  A61K39/29 ,  A61K47/26 ,  C07K16/08 ,  A61K39/00

CPC classification number: C07K16/1018 ,  A61K35/16 ,  A61K39/12 ,  A61K39/145 ,  A61K39/15 ,  A61K39/235 ,  A61K39/29 ,  A61K39/292 ,  A61K39/42 ,  A61K47/26 ,  C07K16/00 ,  C07K16/081 ,  C07K16/082 ,  C07K16/10 ,  C07K16/109 ,  C07K16/1027 ,  A61K2039/545 ,  C07K2317/21 ,  A61K39/42 ,  A61K2300/00

Abstract: The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, serum or plasma, specific antibodies to viral pathogens.

公开(公告)号：US20230181726A1

公开(公告)日：2023-06-15

申请号：US17924646

申请日：2021-05-11

Applicant: Macfarlane Burnet Institute for Medical Research and Public Health Limited ,  CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

Inventor： Heidi DRUMMER ,  Eleanor Jane BARNES ,  Senthil Kumar CHINNAKANNAN

IPC: A61K39/29 ,  A61P31/14

CPC classification number: A61K39/29 ,  A61P31/14 ,  A61K2039/575

Abstract: A pharmaceutical composition comprising a nucleic acid molecule encoding a variable domain deleted E2 polypeptide of HCV (e.g., E2Delta123). The composition is suitable for use, for use, or when used, in the treatment or prevention of HCV infection. The nucleic acid molecule may be DNA or RNA or a modified or synthetic form, or contained within a plasmid, a viral or non-viral vector for vaccination, a polynucleotide expression cassette, or a cell for vector propagation. Methods of administration as prime and boost vaccinations are also provided.

公开(公告)号：US20180169219A1

公开(公告)日：2018-06-21

申请号：US15574427

申请日：2016-07-06

Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

Inventor： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC: A61K39/29 ,  A61K39/295 ,  C12N15/861 ,  A61P31/14 ,  A61P31/04 ,  A61P37/04

CPC classification number: A61K39/29 ,  A61K39/12 ,  A61K39/295 ,  A61K2039/55544 ,  A61P31/04 ,  A61P31/14 ,  A61P37/04 ,  C07K2319/00 ,  C12N15/861 ,  C12N2770/24234

Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20180140699A1

公开(公告)日：2018-05-24

申请号：US15579427

申请日：2016-06-02

Applicant: GREEN CROSS HOLDINGS CORPORATION

Inventor： Yong Won SHIN ,  Dong Il PARK ,  Chung Mo AHN ,  Jong Kyung KIM ,  Dong Hwee LEE

IPC: A61K39/395 ,  A61K39/42 ,  A61K39/29 ,  B01D15/36 ,  A61P43/00 ,  C07K1/18 ,  C07K1/34 ,  A61P1/00 ,  C07K16/10

CPC classification number: A61K39/39525 ,  A61K39/29 ,  A61K39/395 ,  A61K39/42 ,  A61K2039/505 ,  A61P1/00 ,  A61P43/00 ,  B01D15/36 ,  C07K1/18 ,  C07K1/34 ,  C07K16/10

Abstract: The present invention relates to a preparation method of a human plasma-derived hepatitis B immunoglobulin preparation. More specifically, the present invention relates to a preparation method of a human plasma-derived hepatitis B immunoglobulin preparation characterized in that plasma protein fraction II (fraction II) containing human hepatitis B immunoglobulin is dialysis concentrated and then thrombus-producing materials and impurities formed during processes are removed by anion exchange resin and cation exchange resin purification techniques. By using the preparation method of the human plasma-derived hepatitis B immunoglobulin preparation according to the present invention, the efficiency of removing impurities and thrombus-producing materials is increased and a polymer content is maintained, whereby it is possible to produce human hepatitis B immunoglobulin with stable and improved quality.

公开(公告)号：US20180064805A1

公开(公告)日：2018-03-08

申请号：US15784520

申请日：2017-10-16

Applicant: Turnstone Limited Partnership

Inventor： Byram Bridle ,  Brian Lichty ,  Yonghong Wan ,  Jean-Simon Diallo ,  Chantal Lemay ,  John Bell

IPC: A61K39/29 ,  A61K38/16 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K45/06 ,  A61K39/285 ,  A61K39/205 ,  A61K39/17 ,  A61K39/165 ,  A61K39/12 ,  A61K39/04 ,  A61K39/02 ,  A61K39/00 ,  A61K31/165 ,  A61K38/15 ,  A61K38/12 ,  A61K31/713 ,  A61K31/506 ,  A61K31/4745 ,  A61K31/4406 ,  A61K31/4045 ,  A61K31/192

CPC classification number: A61K39/29 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/192 ,  A61K31/4045 ,  A61K31/4406 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/713 ,  A61K35/766 ,  A61K38/12 ,  A61K38/15 ,  A61K38/164 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/04 ,  A61K39/12 ,  A61K39/165 ,  A61K39/17 ,  A61K39/205 ,  A61K39/285 ,  A61K45/06 ,  A61K2039/545 ,  C12N2710/10343 ,  C12N2760/20232 ,  C12N2760/20243 ,  A61K2300/00

Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.

公开(公告)号：US20180055780A1

公开(公告)日：2018-03-01

申请号：US15603992

申请日：2017-05-24

Applicant: Jerome J. Schentag ,  Mary P. Mccourt ,  Lawrence Mielnicki ,  Julie Hughes

Inventor： Jerome J. Schentag ,  Mary P. Mccourt ,  Lawrence Mielnicki ,  Julie Hughes

IPC: A61K9/51 ,  A61K38/14 ,  A61K38/28 ,  A61K31/713 ,  A61K31/12 ,  A61K31/137 ,  A61K31/19 ,  A61K9/127 ,  A61K31/7034 ,  A61K45/06 ,  A61K39/29 ,  A61K39/395 ,  A61K31/546

CPC classification number: A61K9/51 ,  A61K9/127 ,  A61K9/1275 ,  A61K31/12 ,  A61K31/137 ,  A61K31/19 ,  A61K31/546 ,  A61K31/7034 ,  A61K31/713 ,  A61K38/14 ,  A61K38/28 ,  A61K39/29 ,  A61K39/3955 ,  A61K45/06

Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

公开(公告)号：US09885017B2

公开(公告)日：2018-02-06

申请号：US14152448

申请日：2014-01-10

Applicant: Baylor Research Institute ,  Institut National de la Sante et de la Recherche Medicale (INSERM)

Inventor： Helene Dutartre ,  Yves Levy ,  Jacques Banchereau ,  Gerard Zurawski

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/28 ,  A61P37/04 ,  C12N5/0784 ,  A61K39/29 ,  A61K39/12 ,  C07K14/005

CPC classification number: C12N5/0639 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/6056 ,  C07K14/005 ,  C07K16/2851 ,  C07K16/2878 ,  C07K2319/00 ,  C07K2319/33 ,  C12N2770/24222 ,  C12N2770/24234

Abstract: Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.